Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$113,950,808
+$4,889,302 QoQ
Shares Held
2,094,299
-17.6% QoQ
Ownership
0.845%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#27
of 751 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Caisse de depot et placement du Quebec holds $670,874,502 across 12 Biotechnology names. EXEL ranks #3 (17.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
250,608 | $156,264,112 | |
| 2 | INCY |
Incyte Corp
|
1,370,503 | $155,360,220 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
2,094,299 | $113,950,808 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
1,072,439 | $83,939,800 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
1,236,446 | $70,749,440 | |
| 6 | RPRX |
Royalty Pharma plc
|
1,003,953 | $56,291,644 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
85,748 | $25,812,720 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
13,042 | $6,478,352 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $113,950,808 | 2,094,299 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $109,061,506 | 2,542,819 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $118,288,097 | 2,698,793 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $112,524,493 | 2,724,564 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $93,856,502 | 2,129,231 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $98,125,311 | 2,657,782 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $82,730,353 | 2,484,395 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $14,979,066 | 577,228 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||